Well yes, but of course we have to wait until May for those. It's a fair point that there is a world of difference between 100% of the patients living 1 day longer and 5% of the patients being completely cured.
But in my very humble opinion (and why I bought some on the open this morning) that even if we take the worst case with the SIRFLOX results (i.e. Primary goal not achieved, Secondary goal achieved statistically but with minimal clinical significance) then the current price of $18 values the company at about 45 p/e. We know already that revenue grew 37% in H1, so if that growth is maintained in H2 the PE drops to 31 and in in 2015-16 the PE drops to 23.
And the extra kicker is that the results might not be the absolute worst, and other studies in the future might widen the potential use of SIR Spheres.
SRX Price at posting:
$18.70 Sentiment: Buy Disclosure: Held
